Lentiviral Vector– tag –
-
SNS Insider Analysis: Viral Vector Manufacturing Market Surges as Leading CDMOs Expand Capacity with Advanced AAV and Lentiviral Technologies
SNS Insider India Overview SNS Insider's market overview highlights that the increasing number of gene therapy clinical trials and the reliance on CDMOs are driving growth in the viral vector manufacturing market. Key CDMOs like Fujifilm... -
CAR-T’s Geography Problem: Manufacturing Bottlenecks Limit Access, Advances in Closed Systems and Bioprocessing are Key
pharmaphorum UK Overview CAR-T cell therapy's geographical accessibility is heavily dependent on its manufacturing process, with production costs, turnaround times, and available facilities directly impacting patient access. A critical b... -
Porton Advanced Fortifies End-to-End ATMP CDMO Services with Over 250 Global Clients
Porton Advanced China Overview Porton Advanced is strengthening its end-to-end CDMO solutions for Advanced Therapy Medicinal Products (ATMPs), serving over 250 global customers. The company offers cell engineering CMC services for autolo... -
CDMO Signal Ranks Top FDA & GMP-Compliant Lentiviral Vector Manufacturing CDMOs
CDMO Signal Global Overview CDMO Signal has released a ranking of top Lentiviral Vector (LVV) CDMOs, crucial for ex vivo gene therapy, based on FDA inspection history, GMP certification, clinical program activity, and capacity. LVVs are ... -
PackGene Biotech Accelerates Next-Gen CAR-T Development with Lentiviral and mRNA Technologies
PackGene Biotech China Overview PackGene Biotech is advancing next-generation CAR-T cell development by offering both lentiviral vector (LVV) and mRNA technologies for manufacturing. LVVs are a core technology enabling stable, long-term ... -
European Biotechs Unveil Next-Gen CGT Manufacturing to Cut CAR-T Costs Above €60,000 Per Patient
PharmTech Global Overview European biopharmaceutical companies are spearheading the development of advanced manufacturing technologies to address the high costs and logistical hurdles of Cell and Gene Therapies (CGT). Innovations include... -
SK pharmteco Unveils SKyvec™ Viral Vector Platform, Boosting AAV Productivity by 5-6 Fold for Gene Therapy Development
Contract Pharma Global Overview SK pharmteco has launched its innovative 'SKyvec™ Viral Vector Platform,' designed to accelerate gene therapy development. This platform supports adeno-associated virus (AAV), lentivirus, and adenovirus ve... -
European Biotechs Lead Next-Gen Cell & Gene Therapy Manufacturing Innovation: From Scalable Stem Cells to Clinical CAR Treg Trials
PharmTech ヨーロッパ Overview European biotech companies are pioneering next-generation manufacturing technologies crucial for the commercial viability and accessibility of cell and gene therapies (CGTs), prioritizing scalable allogeneic... -
Engineered Allogeneic Treg Cell Therapy TRX103 Enters Phase 1/2a Clinical Trials for Crohn’s Disease and GvHD Prevention
Frontiers Global Overview The gene-edited allogeneic Treg cell therapy candidate TRX103, designed as a scalable, off-the-shelf application, has commenced Phase 1/2a clinical evaluation for Crohn's disease and Graft-versus-Host Disease (G... -
Advancing Cell Therapy Production: CCRM, OmniaBio, and Avectas Pioneer Automated Hub-and-Spoke Model for CAR-T, iPSC, and Lentiviral Vectors
PR Newswire (CCRM) Canada, アイルランド Overview CCRM and its CDMO subsidiary, OmniaBio, have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This strategic alliance ...
